Be at the forefront of Atopic Dermatitis testing in Australia.
Unlock deeper insights and improve sample management in dermatology research with the SCCA2 ELISA kit.
SCCA (squamous cell carcinoma antigen) is a serine protease inhibitor belonging to serpin superfamily.
SCCA consists of two paralogs SCCA1 (SERPIN B3) and SCCA2 (SERPIN B4, which are independent gene products, albeit with very high-amino-acid homologies of 91%. SCCA2 was, like Periostin, identified as one of the molecules, whose expression is elevated when airway epithelial cells are stimulated with IL-4 and IL-13, two cytokines that are central in allergic responses.
Serum SCCA2 levels in children with atopic dermatitis have been reported From an Institute for Clinical Research to be significantly elevated according to the severity of the disease, even when compared with existing blood tests (see Fig. 2).1
As of June 2025, clinicaltrials.gov has listed 257 interventional or observational studies for atopic dermatitis and SCCA2 could be used in all these studies as stratification parameter for participants, making it an easily accessible biomarker to use. Furthermore, the assay has also been proven to be usable also in allergic skin conditions of other types such as psoriasis.
References:
- Nagao, M., Inagaki, S., Kawano, T., Azuma, Y., Nomura, N., Noguchi, Y., Ohta, S., Kawaguchi, A., Odajima, H., Ohya, Y., Fujisawa, T., & Izuhara, K. (2018). SCCA2 is a reliable biomarker for evaluating pediatric atopic dermatitis. The Journal of allergy and clinical immunology, 141(5), 1934–1936.e11. https://doi.org/10.1016/j.jaci.2018.01.021
